The paths to neurodegeneration in genetic parkinson’s disease

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 9, 2014, Pages 1485-1512

  Abdel Salam, Omar M E ^a  

^a NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

Genetic studies; Mitochondria; Oxidative stress; Parkinson s disease (PD); Ubiquitin proteasome pathway

Indexed keywords

ALPHA SYNUCLEIN; DJ 1 PROTEIN; DOPAMINE; FBX 07 PROTEIN; LEUCINE RICH REPEAT KINASE 2; PARKIN; PESTICIDE; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEASOME; PROTEIN; UCH L1 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC NERVE CELL; DROSOPHILA MELANOGASTER; ENVIRONMENTAL EXPOSURE; FAMILIAL DISEASE; GENE; GENE DOSAGE; GENE IDENTIFICATION; GENE LOCATION; GENE LOCUS; GENE MUTATION; GLIOSIS; HUMAN; LEWY BODY; MITOCHONDRIAL DYNAMICS; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN LOCALIZATION; SUBSTANTIA NIGRA PARS COMPACTA; SYNAPTIC TRANSMISSION;

EID: 84920626684     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527313666140806142955     Document Type: Article

References (449)

1. Parkinson J. An essay on the shaking palsy. 1817. J Neuropsychiatry Clin Neurosci 2002; 14(2): 223-36.
2. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973; 20(4): 415-55.
3. Zigmond MJ, Burke RE. Pathophysiology of Parkinson’S disease In: Neuropsychopharmacology: The Fifth Generation of Progress. Fifth edn; Davis KL, Charney D, Coyle JT, Nemeroff C, Eds.: Lippincott Williams & Wilkins: Philadelphia 2002; pp. 1781-93.
4. Graybiel AM. The basal ganglia. Curr Biol 2000; 10: R509-11.
5. Santens P, Boon P, Van Roost D, Caemaert J. The pathophysiology of motor symptoms in Parkinson's disease. Acta Neurol 2003; 103: 129-34.
6. Fahn S. Description of Parkinson’s disease as a clinical syndrome. Ann NY Acad Sci 2003; 991: 1-14.
7. Kempster PA, Hurwitz B, Lees AJ. A new look at James Parkinson's Essay on the Shaking Palsy. Neurology 2007; 69(5): 482-5.
8. Siderowf A, Stern MB. Premotor Parkinson's disease: clinical features, detection, and prospects for treatment. Ann Neurol 2008; 64(Suppl 2): S139-47.
9. Chaudhuri KR, Naidu Y. Early Parkinson’s disease and non-motor issues. J Neurol 2008; 255(Suppl 5): 33-8.
10. Beiske AG, Loge JH, Rønningen A, Svensson E. Pain in Parkinson's disease: Prevalence and characteristics. Pain 2009; 141(1-2): 173-7.
11. Barone P, Antonini A, Colosimo C, et al. The PRiAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord 2009; 24(11): 1641-9.
12. Aarsland D, Brønnick K, Larsen JP, et al. For the Norwegian ParkWest Study Group. Cognitive impairment in incident, untreated Parkinson disease: The Norwegian ParkWest Study. Neurology 2009; 72(13): 1121-6.
13. Mamikonyan E, Moberg PJ, Siderowf A, et al. Mild cognitive impairment is common in Parkinson's disease patients with normal Mini-Mental State Examination (MMSE) scores. Parkinsonism Relat Disord 2009; 15(3): 226-31.
14. Olanow CW, Tatton WG. Etiology and pathogenesis of Parkinson’s disease. Annu Rev Neurosci 1999; 22: 123-44.
15. Giroux ML. Parkinson disease: Managing a complex, progressive disease at all stages. Cleve Clin J Med 2007; 74(5): 313-28.
16. Zhang ZX, Román GC. Worldwide occurrence of Parkinson's disease: an updated review. Neuroepidemiology 1993; 12(4): 195- 208.
17. de Rijk MC, Tzourio C, Breteler MM, et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 62(1): 10-5.
18. von Campenhausen S, Bornschein B, Wick R, et al. Prevalence and incidence of Parkinson's disease in Europe. Eur Neuropsychopharmacol 2005; 15(4): 473-90.
19. Biskup S, Gerlach M, Kupsch A, et al. Genes associated with Parkinson syndrome. J Neurol 2008; 255 Suppl 5: 8-17.
20. Fujioka S, Wszolek, ZK. Update on genetics of Parkinsonism. Neurodegener Dis 2012; 10: 257-60.
21. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276(5321): 2045-7.
22. Spillantini M. G Divane, A and Goedert M. Assignment of human alpha-synuclein (SNCA) and beta-synuclein (SNCB) genes to chromosomes 4q21 and 5q35. Genomics 1995; 27: 379-81.
23. Krüger R, Kuhn W, Müller T, et al. Ala30 Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998; 18(2): 106-8.
24. Krüger R, Kuhn W, Leenders KL, et al. Familial parkinsonism with synuclein pathology: clinical and PET studies of A30P mutation carriers. Neurology 2001; 56(10): 1355-62.
25. Zarranz JJ, Alegre J, Gómez-Esteban JC, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004; 55(2): 164-73.
26. Singleton AB, Farrer M, Johnson J, et al. Alpha-Synuclein locus triplication causes Parkinson’s disease. Science 2003; 302(5646): 841.
27. Chartier-Harlin MC, Kachergus J, Roumier C, et al. Alphasynuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004; 364(9440): 1167-9.
28. IIbáñez P, Bonnet AM, Débarges B, et al. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 2004; 364(9440): 1169-71.
29. Pankratz N, Nichols WC, Elsaesser VE, et al. Alpha-synuclein and familial Parkinson's disease. Mov Disord 2009; 24(8): 1125-31.
30. Eriksen JL, Przedborski S, Petrucelli L. Gene dosage and pathogenesis of Parkinson's disease. Trends Mol Med 2005; 11(3): 91-6.
31. Clayton DF, George JM. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci 1998; 21(6): 249-54.
32. Shibayama-Imazu T, Okahashi I, Omata K, et al. Cell and tissue distribution and developmental change of neuron specific 14 kDa protein (phosphoneuroprotein 14). Brain Res 1993; 622: 17-25.
33. Kaplan B, Ratner V, Haas E. Alpha-synuclein: its biological function and role in neurodegenerative diseases. J Mol Neurosci 2003; 20(2): 83-92.
34. Maroteaux L, Scheller RH. The rat brain synucleins; family of proteins transiently associated with neuronal membrane. Brain Res Mol Brain Res 1991; 11: 335-43.
35. Ueda K, Fukushima H, Masliah E, et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci USA 1993; 90: 11282-6.
36. Maroteaux L, Campanelli JT, Scheller RH. Synuclein: a neuronspecific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci 1988; 8: 2804-15.
37. Uversky VN. A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders. J Biomol Struct Dyn 2003; 21(2): 211-34.
38. Myhre R, Toft M, Kachergus J, et al. Multiple alpha-synuclein gene polymorphisms are associated with Parkinson's disease in a Norwegian population. Acta Neurol Scand 2008; 118(5): 320-7.
39. Murphy DD, Rueter SM, Trojanowski JQ, Lee VM. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci 2000; 20(9): 3214-20.
40. Jenco JM, Rawlingson A, Daniels B, Morris AJ. Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins. Biochemistry 1998; 37(14): 4901-9.
41. Kamp F, Beyer K. Binding of alpha-synuclein affects the lipid packing in bilayers of small vesicles. J Biol Chem 2006; 281(14): 9251-9.
42. Chandra S, Gallardo G, Fernández-Chacón R, Schlüter OM, Südhof TC. Alpha-synuclein cooperates with CSP alpha in preventing neurodegeneration. Cell 2005; 123(3): 383-96.
43. Kéri S, Nagy H, Myers CE, et al. Risk and protective haplotypes of the alpha-synuclein gene associated with Parkinson's disease differentially affect cognitive sequence learning. Genes Brain Behav 2008; 7(1): 31-6.
44. Ellis CE, Murphy EJ, Mitchell DC, et al. Mitochondrial lipid abnormality and electron transport chain impairment in mice lacking alpha-synuclein. Mol Cell Biol 2005; 25(22): 10190-201.
45. Reeve AK, Park TK, Jaros E, et al. Relationship between mitochondria and α -synuclein: a study of single substantia nigra neurons. Arch Neurol 2012; 69(3): 385-93.
46. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2001; 2: 492-501.
47. Iwatsubo T. Aggregation of alpha-synuclein in the pathogenesis of Parkinson’s disease. J Neurol 2003; 250.
48. Jellinger KA. Formation and development of Lewy pathology: a critical update. J Neurol 2009; 256(Suppl 3): 270-9.
49. Jellinger KA. Recent developments in the pathology of Parkinson's disease. J Neural Transm Suppl 2002; (62): 347-76.
50. Jellinger KA. Neuropathological spectrum of synucleinopathies. Mov Disord 2003; 18 (Suppl 6): S2-12.
51. DelleDonne A, Klos KJ, Fujishiro H, et al. Incidental Lewy body disease and preclinical Parkinson disease. Arch Neurol 2008; 65(8): 1074-80.
52. Jellinger KA. Lewy body-related alpha-synucleinopathy in the aged human brain. J Neural Transm 2004; 111(10-11): 1219-35.
53. Malatynska E, Pinhasov A, Crooke J, et al. Levels of mRNA coding for alpha-, beta-, and gamma-synuclein in the brains of newborn, juvenile, and adult rats. J Mol Neurosci 2006; 29(3): 269- 77.
54. Raghavan R, Kruijff L, Sterrenburg MD, et al. Alpha-synuclein expression in the developing human brain. Pediatr Dev Pathol 2004; 7(5): 506-16.
55. Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24(2): 197-211.
56. Halliday GM, Del Tredici K, Braak H. Critical appraisal of brain pathology staging related to presymptomatic and symptomatic cases of sporadic Parkinson's disease. J Neural Transm Suppl 2006; (70): 99-103.
57. Jellinger KA. Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts. Mov Disord 2012; 27(1): 8-30.
58. Jellinger KA. Synuclein deposition and non-motor symptoms in Parkinson disease. J Neurol Sci 2011; 310(1-2): 107-11.
59. Del Tredici K, Rüb U, De Vos RA, Bohl JR, Braak H. Where does parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol 2002; 61(5): 413-26.
60. Tamura T, Yoshida M, Hashizume Y, Sobue G. Lewy body-related α-synucleinopathy in the spinal cord of cases with incidental Lewy body disease. Neuropathology 2012; 32(1): 13-22.
61. Lebouvier T, Chaumette T, Damier P, et al. Pathological lesions in colonic biopsies during Parkinson’s disease. Gut 2008; 57: 1741-3.
62. Hallett PJ, McLean JR, Kartunen A, Langston JW, Isacson O. α - Synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficits. Neurobiol Dis 2012; 47(2): 258- 67.
63. Miller DW, Hague SM, Clarimon J, et al. Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology 2004; 62(10): 1835-8.
64. Ross OA, Braithwaite AT, Skipper LM, et al. Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol 2008; 63: 743-50.
65. Fujiwara H, Hasegawa M, Dohmae N, et al. Aalpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 2002; 4(2): 160-4.
66. Tofaris GK, Razzaq A, Ghetti B, Lilley KS, Spillantini MG. Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J Biol Chem 2003; 278(45): 44405-11.
67. Liu CW Giasson BI, Lewis KA, et al. A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease. J Biol Chem 2005; 280(24): 22670-8.
68. Brucale M, Sandal M, Di Maio S, et al. Pathogenic mutations shift the equilibria of alpha-synuclein single molecules towards structured conformers. Chembiochem 2009; 10(1): 176-83.
69. Saha AR, Hill J, Utton MA, et al. Parkinson's disease alphasynuclein mutations exhibit defective axonal transport in cultured neurons. J Cell Sci 2004; 117(Pt 7): 1017-24.
70. Ikeda M, Kawarabayashi T, Harigaya Y, et al. Motor impairment and aberrant production of neurochemicals in human alphasynuclein A30P+A53T transgenic mice with alpha-synuclein pathology. Brain Res 2009; 1250: 232-41.
71. Grünblatt E, Mandel S, Jacob-Hirsch J, et al. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm 2004; 111(12): 1543-73.
72. Zhou Y, Gu G, Goodlett DR, et al. Analysis of alpha-synucleinassociated proteins by quantitative proteomics. J Biol Chem 2004; 279(37): 39155-64.
73. Tofaris GK, Layfield R, Spillantini MG. Alpha-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome. FEBS Lett 2001; 509: 22-6.
74. Kim C, Lee SJ. Controlling the mass action of alpha-synuclein in Parkinson's disease. J Neurochem 2008; 107(2): 303-16.
75. Lev N, Melamed E, Offen D. Proteasomal inhibition hypersensitizes differentiated neuroblastoma cells to oxidative damage. Neurosci Lett 2006; 399(1-2): 27-32.
76. Niu C, Mei J, Pan Q, Fu X. Nigral degeneration with inclusion body formation and behavioral changes in rats after proteasomal inhibition. Stereotact Funct Neurosurg 2009; 87(2): 69-81.
77. Riedel M, Goldbaum O, Richter-Landsberg C. alpha-Synuclein promotes the recruitment of tau to protein inclusions in oligodendroglial cells: effects of oxidative and proteolytic stress. J Mol Neurosci 2009; 39(1-2): 226-34.
78. Lindersson E, Beedholm R, Højrup P, et al. Proteasomal inhibition by alpha-synuclein filaments and oligomers. J Biol Chem 2004; 279(13): 12924-34.
79. Alves Da Costa C, Paitel E, Vincent B, Checler F. Alpha-synuclein lowers p53-dependent apoptotic response of neuronal cells. Abolishment by 6-hydroxydopamine and implication for Parkinson's disease. J Biol Chem 2002; 277(52): 50980-4.
80. Alves da Costa C, Dunys J, Brau F, et al. 6-Hydroxydopamine but not 1-methyl-4-phenylpyridinium abolishes alpha-synuclein antiapoptotic phenotype by inhibiting its proteasomal degradation and by promoting its aggregation. J Biol Chem 2006; 281(14): 9824-31.
81. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperonemediated autophagy. Science 2004; 305(5688): 1292-5.
82. Pan T, Kondo S, Le W, Jankovic J. The role of autophagylysosome pathway in neurodegeneration associated with Parkinson's disease. Brain 2008; 131(8): 1969-78.
83. Yu WH, Dorado B, Figueroa HY, et al. Metabolic activity determines efficacy of macroautophagic clearance of pathological oligomeric alpha-synuclein. Am J Pathol 2009; 175(2): 736-47.
84. Lee HJ, Khoshaghideh F, Patel S, Lee SJ. Clearance of alphasynuclein oligomeric intermediates via the lysosomal degradation pathway. J Neurosci 2004; 24(8): 1888-96.
85. Qiao L, Hamamichi S, Caldwell KA, et al. Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity. Mol Brain 2008; 1(1): 17.
86. Lee JT, Wheeler TC, Li L, Chin LS. Ubiquitination of a-synuclein by Siah-1 promotes a-synuclein aggregation and apoptotic cell death. Hum Mol Gen 2008; 17 (6): 906-17.
87. Rott R, Szargel R, Haskin J, et al. Monoubiquitylation of alphasynuclein by seven in absentia homolog (SIAH) promotes its aggregation in dopaminergic cells. J Biol Chem 2008; 283(6): 3316-28.
88. Levin J, Giese A, Boetzel K, et al. Increased alpha-synuclein aggregation following limited cleavage by certain matrix metalloproteinases. Exp Neurol 2009; 215(1): 201-8.
89. Norris EH, Uryu K, Leight S, et al. Pesticide exposure exacerbates α-synucleinopathy in an A53T transgenic mouse model. Am J Pathol 2007; 170: 658-66.
90. Kühn K, Wellen J, Link N, et al. The mouse MPTP model: gene expression changes in dopaminergic neurons. Eur J Neurosci 2003; 17: 1-12.
91. Duka T, Rusnak M, Drolet RE, et al. Alpha-synuclein induces hyperphosphorylation of Tau in the MPTP model of parkinsonism. FASEB J 2006; 20: 2302-12.
92. Yu WH, Matsuoka Y, Sziráki I, et al. Increased dopaminergic neuron sensitivity to 1-methyl-4-phenyl-1: 2: 3: 6- tetrahydropyridine (MPTP) in transgenic mice expressing mutant A53T alpha-synuclein. Neurochem Res 2008; 33: 902-11.
93. Fan GH, Zhou HY, Yang H, Chen SD. Heat shock proteins reduce alpha-synuclein aggregation induced by MPP+ in SK-N-SH cells. FEBS Lett 2006; 580(13): 3091-8.
94. Hayashita-Kinoh H, Yamada M, Yokota T, Mizuno Y, Mochizuki H. Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model. Biochem Biophys Res Commun 2006; 341(4): 1088-95.
95. Gorell JM, Johnson CC, Rybicki BA, et al. Occupational exposures to metals as risk factors for Parkinson's disease. Neurology 1997; 48(3): 650-8.
96. Gorell JM, Johnson CC, Rybicki BA, et al. Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. Neurotoxicology 1999; 20(2-3): 239-47.
97. Fabrizio E, Vanacore N, Valente M, Rubino A, Meco G. High prevalence of extrapyramidal signs and symptoms in a group of Italian dental technicians. BMC Neurol 2007; 7: 24.
98. Kaur D, Lee D, Ragapolan S, Andersen JK. Glutathione depletion in immortalized midbrain-derived dopaminergic neurons results in increases in the labile iron pool: implications for Parkinson's disease. Free Radic Biol Med 2009; 46(5): 593-8.
99. Gerlach M, Double KL, Ben-Shachar D, et al. Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson´s disease. Neurotoxicity Res 2003; 5(1-2): 35-44.
100. Shamoto-Nagai M, Maruyama W, Yi H, et al. Neuromelanin induces oxidative stress in mitochondria through release of iron: mechanism behind the inhibition of 26S proteasome. J Neural Transm 2006; 113: 633-44.
101. Golts N, Snyder H, Frasier M, et al. Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein. J Biol Chem 2002; 277(18): 16116-23.
102. Kostka M, Högen T, Danzer KM, et al. Single particle characterization of iron-induced pore-forming alpha-synuclein oligomers. J Biol Chem 2008; 283(16): 10992-1003.
103. Munishkina LA, Fink AL, Uversky VN. Concerted action of metals and macromolecular crowding on the fibrillation of alphasynuclein. Protein Pept Lett 2008; 15(10): 1079-85.
104. Kayed R, Sokolov Y, Edmonds B, et al. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem 2004; 279(45): 46363-6.
105. Olivares D, Huang X, Branden L, Greig NH, Rogers JT. Physiological and pathological role of alpha-synuclein in Parkinson's disease through iron mediated oxidative stress; the role of a putative iron-responsive element. Int J Mol Sci 2009; 10(3): 1226-60.
106. Li J, Zhu M, Manning-Bog AB, Di Monte DA, Fink AL. Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease. FASEB J 2004; 18(9): 962-4.
107. Mazzulli JR, Mishizen AJ, Giasson BI, et al. Cytosolic catechols inhibit SNCA aggregation and facilitate the formation of intracellular soluble oligomeric intermediates. J Neurosci 2006; 26(39): 10068-78.
108. Pham CL, Leong SL, Ali FE, et al. Dopamine and the dopamine oxidation product 5: 6-dihydroxylindole promote distinct onpathway and off-pathway aggregation of alpha-synuclein in a pHdependent manner. J Mol Biol 2009; 387(3): 771-85.
109. van de Berg WD, Hepp DH, Dijkstra AA, et al. Patterns of alphasynuclein pathology in incidental cases and clinical subtypes of Parkinson's disease. Parkinson Relat Disord 2012; 18 Suppl 1: 28- 30.
110. Volpicelli-Daley LA, Luk KC, Patel TP, et al. Exogenous α - synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 2011; 72(1): 57-71.
111. Decressac M, Mattsson B, Lundblad M, Weikop P, Björklund A. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α -synuclein in midbrain dopamine neurons. Neurobiol Dis 2012; 45(3): 939-53.
112. Halliday GM, Ophof A, Broe M, et al. Alpha-Synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. Brain 2005; 128(11): 2654-64.
113. Dalfó E, Ferrer I. Early alpha-synuclein lipoxidation in neocortex in Lewy body diseases. Neurobiol Aging 2008; 29(3): 408-17.
114. Dickson DW, Fujishiro H, DelleDonne A, et al. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol 2008; 115(4): 437-44.
115. Uchihara T, Paulus W. Research into neurodegenerative disease: an entangled web of mice and men. Acta Neuropathol 2008; 115(1): 1-4.
116. Del Tredici K, Braak H. A not entirely benign procedure: progression of Parkinson's disease. Acta Neuropathol 2008; 115(4): 379-84.
117. Watson JB, Hatami A, David H, et al. Alterations in corticostriatal synaptic plasticity in mice overexpressing human alpha-synuclein. Neuroscience 2009; 159(2): 501-13.
118. Borghi R, Marchese R, Negro A, et al. Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci Lett 2000; 287(1): 65-7.
119. El-Agnaf OM, Salem SA, Paleologou KE, et al. Alpha-synuclein implicated in Parkinson’s disease is present in extracellular biological fluids, including human plasma. FASEB J 2003; 17(13): 1945-7.
120. Lee PH, Lee G, Park HJ, et al. The plasma alpha-synuclein levels in patients with Parkinson’s disease and multiple system atrophy. J Neural Transm 2006; 113: 1435-9.
121. Tokuda T, Salem SA, Allsop D, et al. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun 2006; 349(1): 162-6.
122. El-Agnaf OM, Salem SA, Paleologou KE, et al. Detection of oligomeric forms of SNCAprotein in human plasma as a potential biomarker for Parkinson’s disease. FASEB J 2006; 20 (3): 419-25.
123. Noguchi-Shinohara M, Tokuda T, Yoshita M, et al. CSF alphasynuclein levels in dementia with Lewy bodies and Alzheimer's disease. Brain Res 2009; 1251: 1-6.
124. Ohrfelt A, Grognet P, Andreasen N, et al. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci Lett 2009; 450(3): 332-5.
125. Michell AW, Luheshi LM, Barker RA. Skin and platelet alphasynuclein as peripheral biomarkers of Parkinson's disease. Neurosci Lett 2005; 24: 381(3): 294-8.
126. Taraskina AE, Filimonov VA, Kozlovskaya YA, et al. High level of alpha-synuclein mRNA in peripheral lymphocytes of patients with alcohol dependence syndrome. Bull Exp Biol Med 2008; 146(5): 609-11.
127. Abeliovich A, Schmitz Y, Farinas I, et al. Mice lacking alphasynuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000; 25 (1): 239-52.
128. Klivenyi P, Siwek D, Gardian G, et al. Mice lacking alphasynuclein are resistant to mitochondrial toxins. Neurobiol Dis 2006; 21: 541-8.
129. Martin LJ, Pan Y, Price AC, et al. Parkinson's disease alphasynuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J Neurosci 2006; 26(1): 41-50.
130. Zhou W, Milder JB, Freed CR. Transgenic mice overexpressing tyrosine-to-cysteine mutant human α -synuclein. A progressive neurodegenerative model of diffuse lewy body disease. J Biol Chem 2008; 283(15): 9863-70.
131. Lo Bianco C, Ridet JL, Schneider BL, Deglon N, Aebischer P. alpha-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson’s disease. Proc Natl Acad Sci USA 2002; 99: 10813-8.
132. Lauwers E, Bequé D, Van Laere K, et al. Non-invasive imaging of neuropathology in a rat model of alpha-synuclein overexpression. Neurobiol Aging 2007; 28(2): 248-57.
133. Eslamboli A, Romero-Ramos M, Burger C, et al. Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. Brain 2007; 130: 799-815.
134. Tofaris GK, Garcia Reitböck P, Humby T, et al. Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alphasynuclein(1-120): implications for Lewy body disorders. J Neurosci 2006; 26(15): 3942-50.
135. Zhou W, Freed CR. Tyrosine-to-cysteine modification of human alpha-synuclein enhances protein aggregation and cellular toxicity. J Biol Chem 2004; 279(11): 10128-35.
136. Zhou W, Milder JB, Freed CR. Transgenic mice overexpressing tyrosine-to-cysteine mutant human alpha-synuclein: a progressive neurodegenerative model of diffuse Lewy body disease. J Biol Chem 2008; 283(15): 9863-70.
137. Stefanis L, Larsen KE, Rideout HJ, Sulzer D, Greene LA. Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J Neurosci 2001; 21(24): 9549-60.
138. Lehmensiek V, Tan EM, Liebau S, et al. Dopamine transportermediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant alpha-synucleins related to Parkinson's disease. Neurochem Int 2006; 48(5): 329-40.
139. Dawson TM, Mandir A, Lee M. Animal models of PD: pieces of the same puzzle? Neuron 2002; 35: 219-22.
140. Periquet M, Fulga T, Myllykangas L, Schlossmacher MG, Feany MB. Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo. J Neurosci 2007; 27(12): 3338-46.
141. Park SS, Lee D. Selective loss of dopaminergic neurons and formation of Lewy body-like aggregations in alpha-synuclein transgenic fly neuronal cultures. Eur J Neurosci 2006; 23(11): 2908-14.
142. Lam HA, Wu N, Cely I, et al. Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human α -synuclein. J Neurosci Res 2011; 89(7): 1091-102.
143. Wu N, Joshi PR, Cepeda C, Masliah E, Levine MS. Alphasynuclein overexpression in mice alters synaptic communication in the corticostriatal pathway. J Neurosci Res 2010; 88(8): 1764-76.
144. Gaugler MN, Genc O, Bobela W, et al. Nigrostriatal overabundance of α -synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity. Acta Neuropathol 2012; 123(5): 653-69.
145. Chung CY, Koprich JB, Siddiqi H, Isacson O. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV-synucleinopathy. J Neurosci 2009; 29(11): 3365- 73.
146. McNaught KS, Jenner P. Proteasomal function is impaired in substantia nigra in Parkinson’s disease. Neurosci Lett 2001; 297: 191-4.
147. Smith WW, Jiang H, Pei Z, et al. Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alphasynuclein- induced toxicity. Hum Mol Gent 2005; 14 (24): 3801-11.
148. Chen L, Thiruchelvam MJ, Madura K, Richfield EK. Proteasome dysfunction in aged human alpha-synuclein transgenic mice. Neurobiol Dis 2006; 23(1): 120-6.
149. Martìn-Clemente B, Alvarez-Castelao B, Mayo I, et al. Alpha- Synuclein expression levels do not significantly affect proteasome function and expression in mice and stably transfected PC12 cell lines. J Biol Chem 2004; 279(51): 52984-90.
150. Kawahara K, Hashimoto M, Bar-On P, et al. Alpha-Synuclein aggregates interfere with Parkin solubility and distribution: role in the pathogenesis of Parkinson disease. J Biol Chem 2008; 283(11): 6979-87.
151. von Coelln R, Thomas B, Andrabi SA, et al. Inclusion body formation and neurodegeneration are parkin independent in a mouse model of alpha-synucleinopathy. J Neurosci 2006; 26(14): 3685-96.
152. Recchia A, Debetto P, Negro A, et al. Alpha-Synuclein and Parkinson’s disease. FASEB J 2004; 18: 617-26.
153. Lotharius J, Brundin P. Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson’s disease. Hum Mol Gen 2002; 11: 2395-407.
154. Gómez-Santos C, Giménez-Xavier P, Ferrer I, Ambrosio S. Intranigral dopamine toxicity and alpha-synuclein response in rats. Neurochem Res 2006; 31(7): 861-8.
155. Guo JT, Chen AQ, Kong Q, et al. Inhibition of vesicular monoamine transporter-2 activity in alpha-synuclein stably transfected SH-SY5Y cells. Cell Mol Neurobiol 2008; 28: 35-47.
156. Choi BK, Choi MG, Kim JY, et al. Large α -synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking. Proc Natl Acad Sci USA 2013; 110(10): 4087-92.
157. Mosharov EV, Larsen KE, Kanter E, et al. Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron 2009; 62(2): 218-29.
158. Hasegawa T, Matsuzaki-Kobayashi M, Takeda A, et al. Alphasynuclein facilitates the toxicity of oxidized catechol metabolites: implications for selective neurodegeneration in Parkinson's disease. FEBS Lett 2006; 580(8): 2147-52.
159. Park SS, Schulz EM, Lee D. Disruption of dopamine homeostasis underlies selective neurodegeneration mediated by alpha-synuclein. Neurosci Lett 2004; 367(1): 34-9.
160. Yu S, Zuo X, Li Y, et al. Inhibition of tyrosine hydroxylase expression in alpha-synuclein-transfected dopaminergic neuronal cells. Neurosci Lett 2008; 435(1): 24-9.
161. Parihara MS, Parihara A, Fujitab M, Hashimotob M, Ghafourifara P. Mitochondrial association of alpha-synuclein causes oxidative stress. Cell Mol Life Sci 2008; 65: 1272-84.
162. Devi L, Raghavendran V, Prabhu BM, Avadhani NG, Anandatheerthavarada HK. Mitochondrial import and accumulation of alpha-synuclein impair complex i in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem 2008; 283 (14): 9089-9100.
163. Furukawa K, Matsuzaki-Kobayashi M, Hasegawa T, et al. Plasma membrane ion permeability induced by mutant alpha-synuclein contributes to the degeneration of neural cells. J Neurochem 2006; 97(4): 1071-7.
164. Fujita Y, Ohama E, Takatama M, Al-Sarraj S, Okamoto K. Fragmentation of Golgi apparatus of nigral neurons with alphasynuclein- positive inclusions in patients with Parkinson's disease. Acta Neuropathol 2006; 112(3): 261-5.
165. Gosavi N, Lee HJ, Lee JS, Patel S, Lee SJ. Golgi fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion. J Biol Chem 2002; 277(50): 48984-92.
166. Cooper AA, Gitler AD, Cashikar A, et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 2006; 313(5785): 324-8.
167. Gitler AD, Bevis BJ, Shorter J, et al. The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc Natl Acad Sci USA 2008; 105(1): 145-50.
168. Freeman D, Cedillos R, Choyke S, et al. Alpha-synuclein induces lysosomal rupture and cathepsin dependent reactive oxygen species following endocytosis. PLoS One 2013; 8(4): e62143.
169. Duka T, Duka V, Joyce JN, Sidhu A. Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models. FASEB J 2009; 23(9): 2820-30.
170. Bayir H, Kapralov AA, Jiang J, et al. Peroxidase mechanism of lipid-dependent cross-linking of synuclein with cytochrome C: protection against apoptosis versus delayed oxidative stress in Parkinson disease. J Biol Chem 2009; 284(23): 15951-69.
171. Xun Z, Kaufman TC, Clemmer DE. Proteome response to the panneural expression of human wild-type alpha-synuclein: a Drosophila model of Parkinson's disease. J Proteome Res 2008; 7(9): 3911-21.
172. Trinh K, Moore K, Wes PD, et al. Induction of the phase II detoxification pathway suppresses neuron loss in Drosophila models of Parkinson's disease. J Neurosci 2008; 28(2): 465-72.
173. Griffin WS, Liu L, Li Y, Mrak RE, Barger SW. Interleukin-1 mediates Alzheimer and Lewy body pathologies. J Neuroinflamm 2006; 3: 5.
174. Chung CY, Koprich JB, Siddiqi H, Isacson O. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J Neurosci 2009; 29(11): 3365-73.
175. Gao HM, Kotzbauer PT, Uryu K, et al. Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J Neurosci 2008; 28(30): 7687-98.
176. Shavali S, Combs CK, Ebadi M. Reactive macrophages increase oxidative stress and alpha-synuclein nitration during death of dopaminergic neuronal cells in co-culture: relevance to Parkinson's disease. Neurochem Res 2006; 31(1): 85-94.
177. Di Matteo V, Pierucci M, Benigno A, et al. Involvement of nitric oxide in nigrostriatal dopaminergic system degeneration: a neurochemical study. Ann NY Acad Sci 2009; 1155; 309-15.
178. Theodore S, Cao S, McLean PJ, Standaert DG. Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J Neuropathol Exp Neurol 2008; 67(12): 1149- 58.
179. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392(6676): 605-8.
180. Lücking CB, Dürr A, Bonifati V, et al. French Parkinson's Disease Genetics Study Group; European Consortium on Genetic Susceptibility in Parkinson's Disease. Association between earlyonset Parkinson's disease and mutations in the parkin gene. N Engl J Med 2000; 342(21): 1560-7.
181. Matsumine H, Saito M, Shimoda-Matsubayashi S, et al. Localization of a gene for an autosomal recessive form of juvenile Parkinsonism to chromosome 6q25.2-27. Am J Hum Genet 1997; 60(3): 588-96.
182. Jones AC, Yamamura Y, Almasy L, et al. Autosomal recessive juvenile parkinsonism maps to 6q25.2-q27 in four ethnic groups: detailed genetic mapping of the linked region. Am J Hum Genet 1998; 63(1): 80-7.
183. Asakawa S, Tsunematsu Ki, Takayanagi A, et al. The genomic structure and promoter region of the human parkin gene. Biochem Biophys Res Commun 2001; 286(5): 863-8.
184. Shimizu N, Asakawa S, Minoshima S, et al. PARKIN as a pathogenic gene for autosomal recessive juvenile parkinsonism. J Neural Transm Suppl 2000; (58): 19-30.
185. Fishman PS, Oyler GA. Significance of the parkin gene and protein in understanding Parkinson's disease. Curr Neurol Neurosci Rep 2002; 2(4): 296-302.
186. Klein C, Schlossmacher MG. Parkinson disease genetics: Implications for neurological care. Nat Clin Neurol 2006; 2 (3): 136-46.
187. Lu CS, Chou YH, Weng YH, Chen RS. Genetic and DAT imaging studies of familial parkinsonism in a Taiwanese cohort. J Neural Transm 2006(Suppl); 70: 235-40.
188. Reetz K, Siebner HR, Gaser C, et al. Premotor gray matter volume is associated with clinical findings in idiopathic and genetically determined Parkinson’s disease. Open Neuroimaging J 2008; 2: 102-5.
189. Bonifati V, De Michele G, Lücking CB, et al. The parkin gene and its phenotype. Neurol Sci 2001; 22: 51-2.
190. Moran LB, Croisier E, Duke DC, et al. Analysis of alphasynuclein, dopamine and parkin pathways in neuropathologically confirmed parkinsonian nigra. Acta Neuropathol 2007; 113(3): 253-63.
191. Shimura H, Hattori N, Kubo Si, et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 2000; 25(3): 302-5.
192. Lorick KL, Jensen JP, Fang S, et al. RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc Natl Acad Sci USA 1999; 96(20): 11364-9.
193. D'Agata V, Grimaldi M, Pascale A, Cavallaro S. Regional and cellular expression of the parkin gene in the rat cerebral cortex. Eur J Neurosci 2000; 12(10): 3583-8.
194. D'Agata V, Zhao W, Pascale A, et al. Distribution of parkin in the adult rat brain. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26(3): 519-27.
195. D'Agata V, Zhao W, Cavallaro S. Cloning and distribution of the rat parkin mRNA. Brain Res Mol Brain Res 2000; 75(2): 345-9.
196. Ledesma MD, Galvan C, Hellias B, Dotti C, Jensen PH. Astrocytic but not neuronal increased expression and redistribution of parkin during unfolded protein stress. J Neurochem 2002; 83(6): 1431-40.
197. Li H, Guo M. Protein degradation in Parkinson disease revisited: it’s complex. J Clin Invest 2009; 119(3): 442-4.
198. McNaught KS, Olanow CW. Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson's disease. Ann Neurol 2003; 53(Suppl 3): S73-84.
199. Moore DJ. Parkin: a multifaceted ubiquitin ligase. Biochem Soc Trans 2006; 34(5): 749-53.
200. McNaught KS, Belizaire R, Jenner P, Olanow CW, Isacson O. Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease. Neurosci Lett 2002; 326(3): 155-8.
201. Beyer K, Domingo-Sàbat M, Ariza A. Molecular pathology of lewy body diseases. Int J Mol Sci 2009; 10(3): 724-45.
202. Schlehe JS, Lutz AK, Pilsl A, et al. Aberrant folding of pathogenic Parkin mutants: aggregation versus degradation. J Biol Chem 2008; 283 (20): 13771-9.
203. Schlossmacher MG, Frosch MP, Gai WP, et al. Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am J Pathol 2002; 160(5): 1655-67.
204. Smith W, Margolis RL, Li X, et al. Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. J Neurosci 2005; 25: 5544-52.
205. Cha GH, Kim S, Park J, et al. Parkin negatively regulates JNK pathway in the dopaminergic neurons of Drosophila. Proc Natl Acad Sci USA 2005; 102(29): 10345-50.
206. Yamada M, Mizuno Y, Mochizuki H. Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease Hum Gene Ther 2005; 16(2): 262-70.
207. Yang H, Zhou HY, Li B, Chen SD. Neuroprotection of Parkin against apoptosis is independent of inclusion body formation. NeuroReport 2005; 16: 1117-21.
208. Hasegawa T, Treis A, Patenge N, et al. Parkin protects against tyrosinase-mediated dopamine neurotoxicity by suppressing stressactivated protein kinase pathways. J Neurochem 2008; 105(5): 1700-15.
209. Khandelwal PJ, Dumanis SB, Feng LR, et al. Parkinson-related parkin reduces α -Synuclein phosphorylation in a gene transfer model. Mol Neurodegener 2010; 5: 47
210. Lee FJ, Liu F, Pristupa ZB, Niznik HB. Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J 2001; 15: 916- 26.
211. Moszczynska A, Saleh J, Zhang H, et al. Parkin disrupts the alphasynuclein/ dopamine transporter interaction: consequences toward dopamine-induced toxicity. J Mol Neurosci 2007; 32(3): 217-27.
212. Henn IH, Bouman L, Schlehe JS, et al. Parkin mediates neuroprotection through activation of IkappaB kinase/nuclear factor-kappaB signaling. J Neurosci 2007; 27(8): 1868-78.
213. Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 2002; 3: 221-7.
214. Kaltschmidt B, Widera D, Kaltschmidt C. Signaling via NFkappaB in the nervous system. Biochim Biophys Acta 2005; 1745(3): 287-99.
215. Mattson MP, Meffert MK. Roles for NF-kappaB in nerve cell survival, plasticity, and disease. Cell Death Differ 2006; 13(5): 852-60.
216. Helton TD, Otsuka T, Lee M., Mu Y, Ehlers MD. Pruning and loss of excitatory synapses by the parkin ubiquitin ligase. Proc Natl Acad Sci USA 2008; 105(49): 19492-7.
217. LaVoie MJ, Cortese GP, Ostaszewski BL, Schlossmacher MG. The effects of oxidative stress on parkin and other E3 ligases. J Neurochem 2007; 103(6): 2354-68.
218. Wong E., Tan JM, Wang C, et al. Relative sensitivity of parkin and other cysteine-containing enzymes to stress-induced solubility alterations. J Biol Chem 2007; 282(16): 12310-8.
219. Jiang H, Jiang Q, Liu W, Feng J. Parkin suppresses the expression of monoamine oxidases. J Biol Chem 2006; 281 (13): 8591-9
220. Feng J. Microtubule: a common target for parkin and Parkinson's disease toxins. Neuroscientist 2006; 12(6): 469-76.
221. Klein RL, Dayton RD, Henderson KM, Petrucelli L. Parkin is protective for substantia nigra dopamine neurons in a tau gene transfer neurodegeneration model. Neurosci Lett 2006; 401(1-2): 130-5.
222. Moussa CE. Parkin attenuates wild-type tau modification in the presence of beta-amyloid and alpha-synuclein. J Mol Neurosci 2009; 37(1): 25-36.
223. Lim MK, Kawamura T, Ohsawa Y, et al. Parkin interacts with LIM Kinase 1 and reduces its cofilin-phosphorylation activity via ubiquitination. Exp Cell Res 2007; 313(13): 2858-74.
224. Ren Y, Feng J. Rotenone selectively kills serotonergic neurons through a microtubule-dependent mechanism. J Neurochem 2007; 103(1): 303-11.
225. Ren Y, Jiang H, Yang F, Nakaso K, Feng J. Parkin protects dopaminergic neurons against microtubule-depolymerizing toxins by attenuating microtubule-associated protein kinase activation. J Biol Chem 2009; 284(6): 4009-17.
226. Inzelberg R, Jankovic J. Are Parkinson disease patients protected from some but not all cancers? Neurology 2007; 69(15): 1542-50.
227. Staropoli JF. Tumorigenesis and neurodegeneration: two sides of the same coin? Bioessays 2008; 30(8): 719-27.
228. Liu M, Aneja R, Sun X, et al. Parkin regulates Eg5 expression by Hsp70 ubiquitination-dependent inactivation of c-Jun NH2- terminal kinase. J Biol Chem 2008; 283(51): 35783-8.
229. Stichel CC, Zhu XR, Bader V, et al. Mono- and double-mutant mouse models of Parkinson's disease display severe mitochondrial damage. Hum Mol Genet 2007; 16(20): 2377-93.
230. Clark IE, Dodson MW, Jiang C, et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 2006; 441: 1162-6.
231. Poole AC, Thomas RE, Yu S, Vincow ES, Pallanck L. The mitochondrial fusion-promoting factor mitofusin is a substrate of the PINK1/parkin pathway. PLoS One 2010; 5(4): e10054.
232. Poole AC, Thomas RE, Andrews LA, et al. The PINK1/Parkin pathway regulates mitochondrial morphology. Proc Natl Acad Sci USA 2008; 105(5): 1638-43.
233. Deng H, Dodson MW, Huang H, Guo M. The Parkinson's disease genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion in Drosophila. Proc Natl Acad Sci USA 2008; 105(38): 14503-8.
234. Narendra D, Tanaka A, Suen DF, Youle RJ. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol 2008; 183(5): 795-803.
235. Narendra D, Tanaka A, Suen DF, Youle RJ. Parkin-induced mitophagy in the pathogenesis of Parkinson disease. Autophagy 2009; 5(5): 706-8.
236. Shiba K, Arai T, Sato S, et al. Parkin stabilizes PINK1 through direct interaction. Biochem Biophys Res Commun 2009; 383(3): 331-5.
237. Rosen KM, Veereshwarayya V, Moussa CE, et al. Parkin protects against mitochondrial toxins and beta-amyloid accumulation in skeletal muscle cells. J Biol Chem 2006; 281(18): 12809-16.
238. Yao D, Gu Z, Nakamura T, et al. Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. Proc Natl Acad Sci USA 2004; 101(29): 10810-4.
239. McNaught KS, Jackson T, JnoBaptiste R, Kapustin A, Olanow CW. Proteasomal dysfunction in sporadic Parkinson's disease. Neurology 2006; 66(10 Suppl 4): S37-49.
240. Ardley HC, Scott GB, Rose SA, et al. Inhibition of proteasomal activity causes inclusion formation in neuronal and non-neuronal cells overexpressing parkin. Mol Biol Cell 2003; (14): 4541-56.
241. Xiong H, Wang D, Chen L, et al. Parkin.; PINK1: and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation. J Clin Invest 2009; 119(3): 650-60.
242. Fukae J, Sato S, Shiba K, et al. Programmed cell death-2 isoform1 is ubiquitinated by parkin and increased in the substantia nigra of patients with autosomal recessive Parkinson's disease. FEBS Lett 2009; 583(3): 521-5.
243. Itier JM, Ibanez P, Mena MA, et al. Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum Mol Genet 2003; 12(18): 2277-91.
244. Jiang H, Jiang Q, Feng J. Parkin increases dopamine uptake by enhancing the cell surface expression of dopamine transporter. J Biol Chem 2004; 279(52): 54380-6.
245. Lim KL, Chew KC, Tan JM, et al. Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. J Neurosci 2005; 25(8): 2002-9.
246. Wakabayashi K, Engelender S, Yoshimoto M, et al. Synphilin-1 is present in Lewy bodies in Parkinson’s disease. Ann Neurol 2000; 47: 521-3.
247. Marx FP, Soehn AS, Berg D, et al. The proteasomal subunit S6 ATPase is a novel synphilin-1 interacting protein--implications for Parkinson's disease. FASEB J 2007; 21(8): 1759-67.
248. Avraham E, Rott R, Liani E, Szargel R, Engelender S. Phosphorylation of Parkin by the cyclin-dependent kinase 5 at the linker region modulates its ubiquitin-ligase activity and aggregation. J Biol Chem 2007; 282(17): 12842-50.
249. Rubio de la Torre E, Luzón-Toro B, Forte-Lago I, et al. Combined kinase inhibition modulates parkin inactivation. Hum Mol Genet 2009; 18(5): 809-23.
250. Kahns S, Kalai M, Jakobsen LD, et al. Caspase-1 and caspase-8 cleave and inactivate cellular parkin. J Biol Chem 2003; 278(26): 23376-80.
251. van Duijn CM, Dekker MC, Bonifati V, et al. Park7: a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. Am J Hum Genet 2001; 69(3): 629-34.
252. Bonifati V, Breedveld GJ, Squitieri F, et al. Localization of autosomal recessive early-onset parkinsonism to chromosome 1p36 (PARK7) in an independent dataset. Ann Neurol 2002; 51(2): 253- 6.
253. Bonifati V, Rizzu P, van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003; 299(5604): 256-9.
254. Abou-Sleiman PM, Healy DG, Wood NW. Causes of Parkinson’s disease: genetics of DJ-1. Cell Tissue Res 2004; 318: 185-8.
255. Pankratz N, Pauciulo MW, Elsaesser VE, et al. Parkinson Study Group - PROGENI Investigators. Mutations in DJ-1 are rare in familial Parkinson disease. Neurosci Lett 2006; 408(3): 209-13.
256. Abou-Sleiman PM, Healy DG, Quinn N, Lees AJ, Wood NW. The role of pathogenic DJ-1 mutations in Parkinson’s disease. Ann Neurol 2003; 54: 283-6.
257. Nagakubo D, Taira T, Kitaura H, et al. DJ-1: a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. Biochem Biophys Res Commun 1997; 231: 509-13.
258. Bandyopadhyay S, Cookson MR. Evolutionary and functional relationships within the DJ1 superfamily. BMC Evol Biol 2004; 4: 6.
259. Canet-Avilés RM, Wilson MA, Miller DW, et al. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci USA 2004; 101(24): 9103-8.
260. Zhang L, Shimoji M, Thomas B, et al. Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. Hum Mol Genet 2005; 14(14): 2063-73.
261. Olzmann JA, Brown K, Wilkinson KD, et al. Familial Parkinson's disease-associated L166P mutation disrupts DJ-1 protein folding and function. J Biol Chem 2004; 279(9): 8506-15.
262. Miller DW, Ahmad R, Hague S, et al. L166P mutant DJ-1: causative for recessive Parkinson's disease, is degraded through the ubiquitin-proteasome system. J Biol Chem 2003; 278(38):36588-95.
263. Bandopadhyay R, Kingsbury AE, Cookson MR, et al. The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. Brain 2004; 127(Pt 2):420-30.
264. Blackinton J, Ahmad R, Miller DW, et al. Effects of DJ-1 mutations and polymorphisms on protein stability and subcellular localization. Brain Res Mol Brain Res 2005; 134(1):76-83.
265. Kotaria N, Hinz U, Zechel S, von Bohlen Und Halbach O. Localization of DJ-1 protein in the murine brain. Cell Tissue Res 2005; 322(3):503-7.
266. Olzmann JA, Bordelon JR, Muly EC, et al. Selective enrichment of DJ-1 protein in primate striatal neuronal processes: implications for Parkinson's disease. J Comp Neurol 2007; 500(3):585-99.
267. Galter D, Westerlund M, Belin AC, Olson L. DJ-1 and UCH-L1 gene activity patterns in the brains of controls, Parkinson and schizophrenia patients and in rodents. Physiol Behav 2007; 92(1- 2):46-53.
268. Yokota T, Sugawara K, Ito K, et al. Down regulation of DJ-1 enhances cell death by oxidative stress, ER stress, and proteasome inhibition. Biochem Biophys Res Commun 2003; 312:1342-8.
269. Takahashi-Niki K, Niki T, Taira T, Iguchi-Ariga SM, Ariga H. Reduced anti-oxidative stress activities of DJ-1 mutants found in Parkinson's disease patients. Biochem Biophys Res Commun 2004320(2):389-97.
270. Taira T, Saito Y, Niki T, et al. DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep 2004; 5(2):213-8.
271. Abou-Sleiman PM, Muqit MM, Wood NW. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci 2006; 7(3):207-19.
272. Yanagisawa D, Kitamura Y, Inden M, et al. DJ-1 protects against neurodegeneration caused by focal cerebral ischemia and reperfusion in rats. J Cereb Blood Flow Metab 2008; 28(3):563-78.
273. Gu L, Cui T, Fan C, et al. Involvement of ERK1/2 signaling pathway in DJ-1-induced neuroprotection against oxidative stress. Biochem Biophys Res Commun 2009; 383(4): 469-74.
274. Shendelman S, Jonason A, Martinat C, Leete T, Kitada A. DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation. PLoS Biol 2004; 2(11):e362.
275. Zhou W, Zhu M, Wilson MA, Petsko GA, Fink AL. The oxidation state of DJ-1 regulates its chaperone activity toward alphasynuclein. J Mol Biol 2006; 356(4):1036-48.
276. Koide-Yoshida S, Niki T, Ueda M, et al. DJ-1 degrades transthyretin and an inactive form of DJ-1 is secreted in familial amyloidotic polyneuropathy. Int J Mol Med 2007; 19(6):885-93.
277. Wang X, Petrie TG, Liu Y, et al. Parkinson's disease-associated DJ-1 mutations impair mitochondrial dynamics and cause mitochondrial dysfunction. J Neurochem 2012; 121(5): 830-9.
278. Goldberg MS, Pisani A, Haburcak M, et al. Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron 2005; 45(4):489-96.
279. Choi J, Sullards MC, Olzmann JA, et al. Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases. J Biol Chem 2006; 281(16):10816-24.
280. Baulac S, Lu H, Strahle J, et al. Increased DJ-1 expression under oxidative stress and in Alzheimer's disease brains. Mol Neurodegener 2009; 4:12.
281. Mullett SJ, Hamilton RL, Hinkle DA. DJ-1 immunoreactivity in human brain astrocytes is dependent on infarct presence and infarct age. Neuropathology 2009; 29(2): 125-31.
282. Waragai M, Wei J, Fujita M, et al. Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease. Biochem Biophys Res Commun 2006; 345(3):967-72.
283. Waragai M, Nakai M, Wei J, et al. Plasma levels of DJ-1 as a possible marker for progression of sporadic Parkinson's disease. Neurosci Lett 2007; 425(1):18-22.
284. Maita C, Tsuji S, Yabe I, et al. Secretion of DJ-1 into the serum of patients with Parkinson's disease. Neurosci Lett 2008; 431(1):86-9.
285. Nural H, He P, Beach T, et al. Dissembled DJ-1 high molecular weight complex in cortex mitochondria from Parkinson's disease patients. Mol Neurodegener 2009; 4:23.
286. Le Naour F, Misek DE, Krause MC, et al. Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. Clin Cancer Res 2001; 7:3328-35.
287. Tian M, Cui YZ, Song GH, et al. Proteomic analysis identifies MMP-9: DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer 2008; 8:241.
288. Hirotani M, Maita C, Niino M, et al. Correlation between DJ-1 levels in the cerebrospinal fluid and the progression of disabilities in multiple sclerosis patients. Mult Scler 2008; 14(8):1056-60.
289. Honbou K, Suzuki NN, Horiuchi M, et al. The crystal structure of DJ-1: a protein related to male fertility and Parkinson’s disease. J Biol Chem 2003; 278: 31380-4.
290. Malgieri G, Eliezer D. Structural effects of Parkinson's disease linked DJ-1 mutations. Protein Sci 2008; 17(5): 855-68.
291. Moore DJ, Zhang L, Troncoso J, et al. Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. Hum Mol Genet 2005; 14(1): 71-84.
292. Kim RH, Smith PD, Aleyasin H, et al. Hypersensitivity of DJ-1- deficient mice to 1-methyl-4-phenyl-1: 2: 3: 6-tetrahydropyrindine (MPTP) and oxidative stress. Proc Natl Acad Sci USA 2005; 102(14): 5215-20.
293. Lev N, Ickowicz D, Barhum Y, et al. DJ-1 protects against dopamine toxicity. J Neural Transm 2009; 116(2): 151-60.
294. van der Brug MP, Blackinton J, Chandran J, et al. RNA binding activity of the recessive parkinsonism protein DJ-1 supports involvement in multiple cellular pathways. Proc Natl Acad Sci USA 2008; 105(29): 10244-9.
295. Zhong N, Kim CY, Rizzu P, et al. DJ-1 transcriptionally upregulates the human tyrosine hydroxylase by inhibiting the sumoylation of pyrimidine tract-binding protein-associated splicing factor. J Biol Chem 2006; 281(30): 20940-8.
296. Ooe H, Taira T, Iguchi-Ariga SM, Ariga H. Induction of reactive oxygen species by bisphenol A and abrogation of bisphenol Ainduced cell injury by DJ-1. Toxicol Sci 2005; 88(1): 114-26.
297. Xu J, Zhong N, Wang H, et al. The Parkinson's disease-associated DJ-1 protein is a transcriptional co-activator that protects against neuronal apoptosis. Hum Mol Genet 2005; 14(9): 1231-41.
298. Yang W, Chen L, Ding Y, Zhuang X, Kang UJ. Paraquat induces dopaminergic dysfunction and proteasome impairment in DJ-1- deficient mice. Hum Mol Genet 2007; 16(23): 2900-10.
299. Inden M, Taira T, Kitamura Y, et al. PARK7 DJ-1 protects against degeneration of nigral dopaminergic neurons in Parkinson's disease rat model. Neurobiol Dis 2006; 24(1): 144-58.
300. Zhou W, Freed CR. DJ-1 up-regulates glutathione synthesis during oxidative stress and inhibits A53T alpha-synuclein toxicity. J Biol Chem 2005; 280(52): 43150-8.
301. Meulener MC, Xu K, Thomson L, Ischiropoulos H, Bonini NM. Mutational analysis of DJ-1 in Drosophila implicates functional inactivation by oxidative damage and aging. Proc Natl Acad Sci USA 2006; 103 (33): 12517-22.
302. Yang Y, Gehrke S, Haque ME, et al. Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling. Proc Natl Acad Sci USA 2005; 102(38): 13670-5.
303. Aleyasin H, Rousseaux MW, Phillips M, et al. The Parkinson's disease gene DJ-1 is also a key regulator of stroke-induced damage. Proc Natl Acad Sci USA 2007; 104(47): 18748-53.
304. Batelli S, Albani D, Rametta R, et al. DJ-1 modulates alphasynuclein aggregation state in a cellular model of oxidative stress: relevance for Parkinson's disease and involvement of HSP70. PLoS One 2008; 3(4): e1884.
305. Junn E, Taniguchi H, Jeong BS, et al. Interaction of DJ-1 with Daxx inhibits apoptosis signal-regulating kinase 1 activity and cell death. Proc Natl Acad Sci USA 2005; 102(27): 9691-6.
306. Clements CM, McNally RS, Conti BJ, Mak TW, Ting JP. DJ-1: a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc Natl Acad Sci USA 2006; 103(41): 15091-6.
307. Hulleman JD, Mirzaei H, Guigard E, et al. Destabilization of DJ-1 by familial substitution and oxidative modifications: implications for Parkinson's disease. Biochemistry 2007; 46(19): 5776-89.
308. Meulener MC, Graves CL, Sampathu DM, et al. DJ-1 is present in a large molecular complex in human brain tissue and interacts with alpha-synuclein. J Neurochem 2005; 93(6): 1524-32.
309. Jin J, Meredith GE, Chen L, et al. Quantitative proteomic analysis of mitochondrial proteins: relevance to Lewy body formation and Parkinson's disease. Brain Res Mol Brain Res 2005; 134(1): 119-38.
310. Bretaud S, Allen C, Ingham PW, Bandmann O. p53-dependent neuronal cell death in a DJ-1-deficient zebrafish model of Parkinson's disease. J Neurochem 2007; 100(6): 1626-35.
311. Fan J, Ren H, Jia N, et al. DJ-1 decreases Bax expression through repressing p53 transcriptional activity. J Biol Chem 2008; 283(7): 4022-30.
312. Ashley AK, Hanneman WH, Katoh T, et al. Analysis of targeted mutation in DJ-1 on cellular function in primary astrocytes. Toxicol Lett 2009; 184(3): 186-91.
313. Waak J, Weber SS, Waldenmaier A, et al. Regulation of astrocyte inflammatory responses by the Parkinson's disease-associated gene DJ-1. FASEB J 2009; 23(8): 2478-89.
314. Paisán-Ruíz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004; 44(4): 595-600.
315. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004; 44(4): 601-7
316. West AB, Moore DJ, Biskup S, et al. Parkinson's diseaseassociated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci USA 2005; 102: 16842-7.
317. Wszolek ZK, Pfeiffer RF, Tsuboi Y, et al. Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology 2004; 62(9): 1619-22.
318. Hernandez DG, Paisán-Ruíz C, McInerney-Leo A, et al. Clinical and positron emission tomography of Parkinson's disease caused by LRRK2. Ann Neurol 2005; 57(3): 453-6.
319. Gilks WP, Abou-Sleiman PM, Gandhi S, et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 2005; 365(9457): 415-6.
320. Khan NL, Jain S, Lynch JM, et al. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 2005; 128(Pt 12): 2786-96.
321. Di Fonzo A, Rohé CF, Ferreira J, et al. Italian Parkinson Genetics Network. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet 2005; 365(9457): 412-5.
322. Papapetropoulos S, Singer C, Ross OA, et al. Clinical heterogeneity of the LRRK2 G2019S mutation. Arch Neurol 2006; 63: 1242-6.
323. Ishihara L, Warren L, Gibson R, et al. Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations. Arch Neurol 2006; 63: 1250-4.
324. Huang Y, Horne MK, Kotschet K, et al. Prevalence and Clinical Features of Common LRRK2 Mutations in Australians with Parkinson's Disease. Mov Disord 2007; 22 (7): 982-9.
325. Covy JP, Yuan W, Waxman EA, et al. Clinical and pathological characteristics of patients with leucine-rich repeat kinase-2 mutations. Mov Disord 2009; 24(1): 32-9.
326. Bonifati V. Parkinson’s disease: the LRRK2-G2019S mutation: opening a novel era in Parkinson’s disease genetics. Eur J Hum Genet 2006; 14: 1061-2.
327. Lesage S, Durr A, Brice A. LRRK2: a link between familial and sporadic Parkinson’s disease? Pathol Biol 2006; 55: 107-10.
328. Floris G, Cannas A, Solla P, et al. Genetic analysis for five LRRK2 mutations in a Sardinian parkinsonian population: importance of G2019S and R1441C mutations in sporadic Parkinson's disease patients. Parkinsonism Relat Disord 2009; 15(4): 277-80.
329. Healy DG, Falchi M, O'Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008; 7(7): 583-90.
330. Gaig C, Martí MJ, Ezquerra M, et al. G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies. J Neurol Neurosurg Psychiatry 2007; 78(6): 626-8.
331. Bras JM, Guerreiro RJ, Ribeiro MH, et al. G2019S Dardarin substitution is a common cause of Parkinson’s disease in a Portuguese cohort. Mov Disord 2005; 20(12): 2005.
332. Li X, Tan YC, Poulose S, et al. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J Neurochem 2007; 3(1): 238-47.
333. Marin I. The Parkinson disease gene LRRK2: evolutionary and structural insights. Mol Biol Evol 2006; 23(12): 2423e33.
334. Mata IF, Wedemeyer WJ, Farrer MJ, Taylor JP, Gallo KA. LRRK2 in Parkinson’s disease: protein domains and functional insights. Trends Neurosci 2006; 29(5): 286e93.
335. Tsika E, Moore DJ. Contribution of GTPase activity to LRRK2- associated Parkinson disease. Small GTPases 2013; 4(3): 164-70.
336. Smith WW, Pei Z, Jiang H, et al. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 2006; 9: 1231-3.
337. West AB, Moore DJ, Choi C, et al. Parkinson’s disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet 2007; 16: 223-32.
338. Hatano T, Kubo S, Imai S, et al. Leucine-rich repeat kinase 2 associates with lipid rafts. Hum Mol Genet 2007; 16(6): 678-90.
339. Alegre-Abarrategui J, Ansorge O, Esiri M, Wade-Martins R. LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease. Neuropathol Appl Neurobiol 2008; 34(3): 272-83.
340. Vitte J, Traver S, Maués De Paula A, et al. Leucine-rich repeat kinase 2 is associated with the endoplasmic reticulum in dopaminergic neurons and accumulates in the core of Lewy bodies in Parkinson disease. J Neuropathol Exp Neurol 2010; 69(9): 959-72.
341. Hakimi M, Selvanantham T, Swinton E, et al. Parkinson's diseaselinked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. J Neural Transm 2011; 118(5): 795-808.
342. Gillardon F, Schmid R, Draheim H. Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity. Neuroscience 2012; 208: 41-8.
343. Greggio E, Zambrano I, Kaganovich A, et al. The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J Biol Chem 2008; 283(24): 16906-14.
344. Smith WW, Pei Z, Jiang H, et al. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci USA 2005; 102(51): 18676-81.
345. MacLeod D, Dowman J, Hammond R, et al. The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 2006; 52(4): 587-93.
346. Anand VS, Reichling LJ, Lipinski K, et al. Investigation of leucinerich repeat kinase 2: enzymological properties and novel assays. FEBS J 2009; 276(2): 466-78.
347. Li X, Tan YC, Poulose S, et al. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J Neurochem 2007; 103(1): 238-47.
348. Lewis PA, Greggio E, Beilina A, et al. The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem Biophys Res Commun 2007; 357(3): 668-71.
349. Lee S, Liu HP, Lin WY, Guo H, Lu B. LRRK2 kinase regulates synaptic morphology through distinct substrates at the presynaptic and postsynaptic compartments of the Drosophila neuromuscular junction. J Neurosci 2010; 30(50): 16959-69.
350. Biskup S, Moore DJ, Celsi F, et al. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol 2006; 60(5): 557e69.
351. Piccoli G, Condliffe SB, Bauer M, et al. LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool. J Neurosci 2011; 31(6): 2225-37.
352. Tong Y, Pisani A, Martella G, et al. R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc Natl Acad Sci USA 2009; 106(34): 14622-7.
353. Li X, Patel JC, Wang J, et al. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J Neurosci 2010; 30(5): 1788-97.
354. Zhu X, Babar A, Siedlak SL, et al. LRRK2 in Parkinson's disease and dementia with Lewy bodies. Mol Neurodegener 2006; 1: 7.
355. Westerlund M, Ran C, Borgkvist A, et al. Lrrk2 and alphasynuclein are co-regulated in rodent striatum. Mol Cell Neurosci 2008; 39(4): 586-91.
356. Miklossy J, Qing H, Guo JP, et al. Lrrk2 and chronic inflammation are linked to pallido-ponto-nigral degeneration caused by the N279K tau mutation. Acta Neuropathol 2007; 114(3): 243-54.
357. Li, Y, Liu W, Oo TF, et al. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci 2009; 12(7): 826-8.
358. Ramonet D, Daher JP, Lin BM, et al. Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One 2011; 6(4): e18568.
359. Liu Z, Wang X, Yu Y, et al. A Drosophila model for LRRK2- linked parkinsonism. Proc Natl Acad Sci USA 2008; 105 (7): 2693-8.
360. Lin CH, Tsai PI, Wu RM, Chien CT. LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of tau by recruiting autoactivated GSK3ß. J Neurosci 2010; 30(39): 13138-49.
361. Niu J, Yu M, Wang C, Xu Z. Leucine-rich repeat kinase 2 disturbs mitochondrial dynamics via Dynamin-like protein. J Neurochem 2012; 122(3): 650-8.
362. Iaccarino C, Crosio C, Vitale C, et al. Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum Mol Genet 2007; 16(11): 1319-26.
363. Wang L, Xie C, Greggio E, et al. The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucinerich repeat kinase 2. J Neurosci 2008; 28(13): 3384-91.
364. Roth JA, Eichhorn M. Down-regulation of LRRK2 in control and DAT transfected HEK cells increases manganese-induced oxidative stress and cell toxicity. Neurotoxicology 2013; 37: 100-7.
365. Lee BD, Shin JH, VanKampen J, et al. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med 2010; 16(9): 998-1000.
366. Yao C, Johnson WM, Gao Y, et al. Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity. Hum Mol Genet 2013; 22(2): 328-44.
367. Stafa K, Trancikova A, Webber PJ, et al. GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1. PLoS Genet 2012; 8(2): 1002526.
368. Dzamko N, Deak M, Hentati F, et al. Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935): disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem J 2010; 430(3): 405-13.
369. Marker DF, Puccini JM, Mockus TE, et al. LRRK2 kinase inhibition prevents pathological microglial phagocytosis in response to HIV-1 Tat protein. J Neuroinflamm 2012; 9: 261.
370. Liu Z, Hamamichi S, Lee BD, et al. Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models. Hum Mol Genet 2011; 20(20): 3933-42.
371. Anglade P, Vyas S, Javoy-Agid F, et al. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol 1997; 12(1): 25-31.
372. Cuervo AM, Wong E. Chaperone-mediated autophagy: roles in disease and aging. Cell Res 201; 24: 92-104.
373. Orenstein SJ, Cuervo AM. Chaperone-mediated autophagy: molecular mechanisms and physiological relevance. Semin Cell Dev Biol 2010; 21(7): 719-26.
374. Orenstein SJ, Kuo SH, Tasset I, et al. Interplay of LRRK2 with chaperone-mediated autophagy. Nat Neurosci 2013; 16(4): 394- 406.
375. Valente EM, Salvi S, Ialongo T, et al. PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann Neurol 2004; 56(3): 336-41.
376. Valente EM, Abou-Sleiman PM, Caputo V, et al. Hereditary earlyonset Parkinson's disease caused by mutations in PINK1. Science 2004; 304(5674): 1158-60.
377. Ibáñez P, Lesage S, Lohmann E, et al. Mutational analysis of the PINK1 gene in early-onset parkinsonism in Europe and North Africa. Brain 2006; 129(Pt 3): 686-94.
378. Valente EM, Bentivoglio AR, Dixon PH, et al. Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6: on human chromosome 1p35-p36. Am J Hum Genet 2001; 68(4): 895-900.
379. Bentivoglio AR, Cortelli P, Valente EM, et al. Phenotypic characterization of autosomal recessive PARK6-linked parkinsonism in three unrelated Italian families. Mov Disord 2001; 16: 999-1006.
380. Albanese A, Valente EM, Romito LM, et al. The PINK1 phenotype can be indistinguishable from idiopathic Parkinson disease. Neurology 2005; 64(11): 1958-60.
381. Bonifati V, Rohé CF, Breedveld GJ, et al. Italian Parkinson Genetics Network. Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology 2005; 65(1): 87-95.
382. Weng YH, Chou YH, Wu WS, et al. PINK1 mutation in Taiwanese early-onset parkinsonism: clinical, genetic, and dopamine transporter studies. J Neurol 2007; 254(10): 1347-55.
383. Gandhi S, Muqit MM, Stanyer L, et al. PINK1 protein in normal human brain and Parkinson's disease. Brain 2006; 129(Pt 7): 1720- 31.
384. Nakajima A, Kataoka K, Hong M, Sakaguchi M, Huh NH. BRPK, a novel protein kinase showing increased expression in mouse cancer cell lines with higher metastatic potential. Cancer Lett 2003; 201(2): 195-201.
385. Silvestri L, Caputo V, Bellacchio E, et al. Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Hum Mol Genet 2005; 14(22): 3477-92.
386. Weihofen A, Ostaszewski B, Minami Y, Selkoe DJ. Pink1 Parkinson mutations, the Cdc37/Hsp90 chaperones and Parkin all influence the maturation or subcellular distribution of Pink1. Hum Mol Genet 2008; 17(4): 602-16.
387. Unoki M, Nakamura Y. Growth-suppressive effects of BPOZ and EGR2: two genes involved in the PTEN signaling pathway. Oncogene 2001; 20(33): 4457-65.
388. Beilina A, Van Der Brug M, Ahmad R, et al. Mutations in PTENinduced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability. Proc Natl Acad Sci USA 2005; 102(16): 5703-8.
389. Franks PW, Scheele C, Loos RJ, et al. Genomic variants at the PINK1 locus are associated with transcript abundance and plasma nonesterified fatty acid concentrations in European whites. FASEB J 2008; 22(9): 3135-45.
390. Weihofen A, Thomas KJ, Ostaszewski BL, Cookson MR, Selkoe DJ. Pink1 forms a multiprotein complex with Miro and Milton, linking Pink1 function to mitochondrial trafficking. Biochemistry 2009; 48: 2045-52.
391. Zhou C, Huang Y, Shao Y, et al. The kinase domain of mitochondrial PINK1 faces the cytoplasm. Proc Natl Acad Sci USA 2008; 105: 12022-7.
392. Petit A, Kawarai T, Paitel E, et al. Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations. J Biol Chem 2005; 280(40): 34025-32.
393. Pridgeon JW, Olzmann JA, Chin LS, Li L. PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biol 2007; 5(7): e172.
394. Qi Z, Yang W, Liu Y, et al. Loss of PINK1 function decreases PP2A activity and promotes autophagy in dopaminergic cells and a murine model. Neurochem Int 2011; 59(5): 572-81.
395. Todd AM, Staveley BE. Pink1 suppresses alpha-synuclein-induced phenotypes in a Drosophila model of Parkinson's disease. Genome 2008; 51(12): 1040-6.
396. Yang Y, Gehrke S, Imai Y, et al. Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc Natl Acad Sci USA 2006; 103(28): 10793-8.
397. Clark IE, Dodson MW, Jiang C, et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 2006; 441(7097): 1162-6.
398. Yang Y, Ouyang Y, Yang L, et al. Pink1 regulates mitochondrial dynamics through interaction with the fission/fusion machinery. Proc Natl Acad Sci USA 2008; 105(19): 7070-5.
399. Cui M, Tang X, Christian WV, Yoon Y, Tieu K. Perturbations in mitochondrial dynamics induced by human mutant PINK1 can be rescued by the mitochondrial division inhibitor mdivi-1. J Biol Chem 2010; 285(15): 11740-52.
400. Kim Y, Park J, Kim S, et al. PINK1 controls mitochondrial localization of Parkin through direct phosphorylation. Biochem Biophys Res Commun 2008; 377(3): 975-80.
401. Exner N, Treske B, Paquet D, et al. Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J Neurosci 2007; 27(45): 12413-8.
402. Yu W, Sun Y, Guo S, Lu B. The PINK1/Parkin pathway regulates mitochondrial dynamics and function in mammalian hippocampal and dopaminergic neurons. Hum Mol Genet 2011; 20(16): 3227- 40.
403. Gautier CA, Kitada T, Shen J. Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress. Proc Natl Acad Sci 2008; 105(32): 11364-9.
404. Gandhi S, Wood-Kaczmar A, Yao Z, et al. PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calciuminduced cell death. Mol Cell 2009; 33(5): 627-38.
405. Abramov AY, Gegg M, Grunewald A, et al. Bioenergetic consequences of PINK1 mutations in Parkinson disease. PLoS One 2011; 6(10): e25622.
406. Liu W, Acín-Peréz R, Geghman KD, et al. Pink1 regulates the oxidative phosphorylation machinery via mitochondrial fission. Proc Natl Acad Sci USA 2011; 108(31): 12920-4.
407. Wang HL, Chou AH, Wu AS, et al. PARK6 PINK1 mutants are defective in maintaining mitochondrial membrane potential and inhibiting ROS formation of substantia nigra dopaminergic neurons. Biochim Biophys Acta 2011; 1812(6): 674-84.
408. Anichtchik O, Diekmann H, Fleming A, et al. Loss of PINK1 function affects development and results in neurodegeneration in zebrafish. J Neurosci 2008; 28(33): 8199-207.
409. Mizuno Y, Hattori N, Yoshino H, et al. Progress in familial Parkinson's disease. J Neural Transm Suppl 2006; (70): 191-204.
410. Edwards YH, Fox MF, Povey S, et al. The gene for human neuron specific ubiquitin C-terminal hydrolase maps to chromosome 4p14. Cytogenet Cell Genet 1991; 58: 1886-7.
411. Edwards YH, Fox MF, Povey S, et al. The gene for human neurone specific ubiquitin C-terminal hydrolase (UCHL1: PGP9.5) maps to chromosome 4p14. Ann Hum Genet 1991; 55(Pt 4): 273-8.
412. Maraganore DM, Lesnick TG, Elbaz A, et al. UCHL1 Global Genetics Consortium. UCHL1 is a Parkinson's disease susceptibility gene. Ann Neurol 2004; 55(4): 512-21.
413. Doran JF, Jackson P, Kynoch PA, Thompson RJ. Isolation of PGP 9.5: a new human neurone-specific protein detected by highresolution two-dimensional electrophoresis. J Neurochem 1983; 40: 1542-7.
414. Galter D, Westerlund M, Belin AC, Olson L. DJ-1 and UCH-L1 gene activity patterns in the brains of controls, Parkinson and schizophrenia patients and in rodents. Physiol Behav 2007; 92(1- 2): 46-53.
415. Wilkinson KD, Lee KM, Deshpande S, et al. The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. Science 1989; 246: 670-73.
416. Cartier AE, Djakovic SN, Salehi A, et al. Regulation of synaptic structure by ubiquitin C-terminal hydrolase L1. J Neurosci 2009; 29(24): 7857-68.
417. Nagamine S, Kabuta T, Furuta A, et al. Deficiency of ubiquitin carboxy-terminal hydrolase-L1 (UCH-L1) leads to vulnerability to lipid peroxidation. Neurochem Int 2010; 57(2): 102-10.
418. Choi J, Levey AI, Weintraub ST, et al. Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J Biol Chem 2004; 279(13): 13256-64.
419. Bheda A, Yue W, Gullapalli A, Shackelford J, Pagano JS. PU.1- dependent regulation of UCH L1 expression in B-lymphoma cells. Leuk Lymphoma 2011; 52(7): 1336-47.
420. Miyoshi Y, Nakayama S, Torikoshi Y, et al. High expression of ubiquitin carboxy-terminal hydrolase-L1 and -L3 mRNA predicts early recurrence in patients with invasive breast cancer. Cancer Sci 2006; 97(6): 523-9.
421. Papa L, Akinyi L, Liu MC, et al. Ubiquitin C-terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury. Crit Care Med 2010; 38(1): 138-44.
422. Mondello S, Linnet A, Buki A, et al. Clinical utility of serum levels of ubiquitin C-terminal hydrolase as a biomarker for severe traumatic brain injury. Neurosurgery 2012; 70(3): 666-75.
423. Bifsha P, Landry K, Ashmarina L, et al. Altered gene expression in cells from patients with lysosomal storage disorders suggests impairment of the ubiquitin pathway. Cell Death Differ 2007; 14(3): 511-23.
424. Elbaz A, Levecque C, Clavel J, et al. S18Y polymorphism in the UCH-L1 gene and Parkinson's disease: evidence for an agedependent relationship. Mov Disord 2003; 18(2): 130-7.
425. Carmine Belin A, Westerlund M, Bergman O, et al. S18Y in ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) associated with decreased risk of Parkinson's disease in Sweden. Parkinsonism Relat Disord 2007; 13(5): 295-8.
426. Kyratzi E, Pavlaki M, Stefanis L. The S18Y polymorphic variant of UCH-L1 confers an antioxidant function to neuronal cells. Hum Mol Genet 2008; 17(14): 2160-71.
427. Xilouri M, Kyratzi E, Pitychoutis PM, et al. Selective neuroprotective effects of the S18Y polymorphic variant of UCHL1 in the dopaminergic system. Hum Mol Genet 2012; 21(4): 874- 89.
428. Liu Z, Meray RK, Grammatopoulos TN, et al. Membraneassociated farnesylated UCH-L1 promotes alpha-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease. Proc Natl Acad Sci USA 2009; 106(12): 4635-40.
429. Kabuta T, Furuta A, Aoki S, Furuta K, Wada K. Aberrant interaction between Parkinson disease-associated mutant UCH-L1 and the lysosomal receptor for chaperone-mediated autophagy. J Biol Chem 2008; 283(35): 23731-8.
430. Kabuta T, Wada K. Insights into links between familial and sporadic Parkinson's disease: physical relationship between UCHL1 variants and chaperone-mediated autophagy. Autophagy 2008; 4(6): 827-9.
431. Cartier AE, Ubhi K, Spencer B, et al. Differential Effects of UCHL1 Modulation on Alpha-Synuclein in PD-Like Models of Alpha-Synucleinopathy. PLoS One 2012; 7(4): e34713.
432. Shimshek DR, Schweizer T, Schmid P, van der Putten PH. Excess SNCAworsens disease in mice lacking ubiquitin carboxy-terminal hydrolase L1. Sci Rep 2012; 2: 262.
433. Van Laar VS, Mishizen AJ, Cascio M, Hastings TG. Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells. Neurobiol Dis 2009; 34(3): 487-500.
434. Di Fonzo A, Dekker MC, Montagna P, et al. FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome. Neurology 2009; 72(3): 240-5.
435. Santoro L, Breedveld GJ, Manganelli F, et al. Novel ATP13A2 (PARK9) homozygous mutation in a family with marked phenotype variability. Neurogenetics 2011; 12(1): 33-9.
436. Park JS, Mehta P, Cooper AA, et al. Pathogenic effects of novel mutations in the P-type ATPase ATP13A2 (PARK9) causing Kufor-Rakeb syndrome, a form of early-onset parkinsonism. Hum Mutat 2011; 32(8): 956-64.
437. Schultheis PJ, Hagen TT, O’Toole KK, et al. Characterization of the P5 subfamily of P-type transport ATPases in mice. Biochem Biophys Res Commun 2004; 323: 731-8.
438. Ramonet D, Podhajska A, Stafa K, et al. PARK9-associated ATP13A2 localizes to intracellular acidic vesicles and regulates cation homeostasis and neuronal integrity. Hum Mol Genet 2012; 21(8): 1725-43.
439. Radi E, Formichi P, Di Maio G, Battisti C, Federico A. Altered apoptosis regulation in Kufor-Rakeb syndrome patients with mutations in the ATP13A2 gene. J Cell Mol Med 2012; 16(8): 1916-23.
440. Dehay B, Martinez-Vicente M, Ramirez A, et al. Lysosomal dysfunction in Parkinson disease: ATP13A2 gets into the groove. Autophagy 2012; 8(9): 1389-91.
441. Dehay B, Ramirez A, Martinez-Vicente M, et al. Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. Proc Natl Acad Sci USA 2012; 109(24): 9611-6.
442. Usenovic M, Tresse E, Mazzulli JR, Taylor JP, Krainc D. Deficiency of ATP13A2 leads to lysosomal dysfunction, α - synuclein accumulation, and neurotoxicity. J Neurosci 2012; 32(12): 240-6.
443. Ugolino J, Fang S, Kubisch C, Monteiro MJ. Mutant Atp13a2 proteins involved in parkinsonism are degraded by ER-associated degradation and sensitize cells to ER-stress induced cell death. Hum Mol Genet 2011; 20(18): 3565-77.
444. Cenciarelli C, Chiaur DS, Guardavaccaro D, et al. Identification of a family of human F-box proteins. Curr Biol 1999; 9(20): 1177-9.
445. Winston JT, Koepp DM, Zhu C, Elledge SJ, Harper JW. A family of mammalian F-box proteins. Curr Biol 1999; 9(20): 1180-2.
446. Nelson DE, Laman HA. Competitive binding mechanism between Skp1 and exportin 1 (CRM1) controls the localization of a subset of F-box proteins. J Biol Chem 2011; 286(22): 19804-15.
447. Deng H, Liang H, Jankovic J. F-box only protein 7 gene in parkinsonian-pyramidal disease. JAMA Neurol 2013; 70(1): 20-4.
448. Zhao T, Severijnen LA, van der Weiden M, et al. FBXO7 Immunoreactivity in α -synuclein-containing inclusions in parkinson disease and multiple system atrophy. J Neuropathol Exp Neurol 2013; 72(6): 482-8.
449. Zhao T, Zondervan-van der Linde H, Severijnen LA, et al. Dopaminergic neuronal loss and dopamine-dependent locomotor defects in Fbxo7-deficient zebrafish. PLoS One 2012; 7(11): e48911.